Mayne Pharma Group Limited
Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women's health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. It operates through three segments: Women's Health, Dermatology, and International. The company provides oral drug delivery systems, as well as contract developmen… Read more
Mayne Pharma Group Limited - Asset Resilience Ratio
Mayne Pharma Group Limited (MAYNF) has an Asset Resilience Ratio of 4.00% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2025)
This chart shows how Mayne Pharma Group Limited's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Mayne Pharma Group Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $40.56 Million | 4.0% |
| Total Liquid Assets | $40.56 Million | 4.00% |
Asset Resilience Insights
- Limited Liquidity: Mayne Pharma Group Limited maintains only 4.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Mayne Pharma Group Limited Industry Peers by Asset Resilience Ratio
Compare Mayne Pharma Group Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
C.Q. Pharmaceutical Holding Co Ltd
SHE:000950 |
Medical Distribution | 0.00% |
|
Shenzhen Glory Medical Co Ltd
SHE:002551 |
Medical Distribution | 10.46% |
|
Shandong Realcan Pharmaceutical Co Ltd
SHE:002589 |
Medical Distribution | -4.18% |
|
Hanmi Science
KO:008930 |
Medical Distribution | 0.06% |
|
BCM Alliance Bhd
KLSE:0187 |
Medical Distribution | 17.12% |
|
Qingdao Baheal Medical INC.
SHE:301015 |
Medical Distribution | 3.50% |
|
Excelsior Medical Co Ltd
TW:4104 |
Medical Distribution | 3.70% |
|
CHC Healthcare Group
TW:4164 |
Medical Distribution | 0.46% |
Annual Asset Resilience Ratio for Mayne Pharma Group Limited (2013–2025)
The table below shows the annual Asset Resilience Ratio data for Mayne Pharma Group Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 4.00% | $40.56 Million | $1.01 Billion | +0.57pp |
| 2024-06-30 | 3.43% | $39.21 Million | $1.14 Billion | -6.79pp |
| 2023-06-30 | 10.22% | $127.53 Million | $1.25 Billion | +10.11pp |
| 2022-06-30 | 0.10% | $1.33 Million | $1.29 Billion | +0.07pp |
| 2019-06-30 | 0.03% | $563.00K | $1.64 Billion | -0.33pp |
| 2018-06-30 | 0.37% | $6.75 Million | $1.83 Billion | +0.04pp |
| 2017-06-30 | 0.32% | $6.21 Million | $1.91 Billion | +0.10pp |
| 2016-06-30 | 0.22% | $3.46 Million | $1.56 Billion | -0.20pp |
| 2015-06-30 | 0.42% | $2.23 Million | $528.95 Million | -0.02pp |
| 2014-06-30 | 0.44% | $1.17 Million | $265.82 Million | -0.34pp |
| 2013-06-30 | 0.78% | $1.82 Million | $233.39 Million | -- |